Cowen & Co. Sticks to Its Buy Rating for Mersana Therapeutics Inc (MRSN)


Cowen & Co. analyst Boris Peaker maintained a Buy rating on Mersana Therapeutics Inc (MRSN) today. The company’s shares opened today at $6.04, close to its 52-week low of $5.56.

According to TipRanks.com, Peaker is a 4-star analyst with an average return of 6.3% and a 41.0% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Stemline Therapeutics Inc, and Y-Mabs Therapeutics Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Mersana Therapeutics Inc with a $21.50 average price target.

See today’s analyst top recommended stocks >>

Based on Mersana Therapeutics Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $12.35 million. In comparison, last year the company had a GAAP net loss of $7.73 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Mersana Therapeutics, Inc. engages in the development and manufacture of antibody drug conjugates to improve patient outcomes in multiple oncology indications. Its lead product candidates are XMT-1522, which focuses on breast cancer and non-small cell lung cancer (NSCLC); and XMT-1536, which targets ovarian cancer and NSCLC. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts